AI's Growing Role in the Patient Access Solutions Market

Healthcare's "front door" is getting a technology overhaul. Every appointment booked, insurance card scanned, and prior authorization submitted is part of what the industry calls patient access — and the software and services that manage it have become one of the more closely watched corners of healthcare IT.

The global patient access solutions market:

  • 2024 market size: USD 2.0 billion
  • 2033 projected market size: USD 4.0 billion
  • CAGR (2025–2033): 7.8%

That near-doubling in under a decade reflects a simple reality: the administrative front end of healthcare — eligibility checks, prior authorizations, scheduling, and financial clearance — has become too complex and too costly to manage manually.

Why the Market Is Growing: Key Drivers

  1. Claim denials are rising fast, and providers are feeling the pressure. According to Experian Health's 2024 survey, almost three out of four providers now report increasing claim denials, up sharply from 43% in 2022. Payer policy changes are also becoming more frequent — 77% of providers report more frequent changes, up from 67% two years earlier — while 67% report longer reimbursement timelines. This mounting administrative burden is a direct driver of demand for automated, front-end solutions that catch errors before a claim is ever submitted.
  2. Insurance verification and prior authorization have become genuinely burdensome. Payers are layering on complex benefit structures and stricter documentation requirements, and manual eligibility checks simply can't keep pace. In the U.S. specifically, physician practices complete an average of 39 prior authorization requests per week, consuming roughly 13 hours of staff time — a workload that is fueling clinician burnout as much as it is driving software adoption.
  3. AI and automation are reshaping what "patient access" even means. Eligibility verification, prior authorization, registration, and denial prediction are increasingly AI-driven. Vendors are layering OCR document capture, natural language processing, predictive denial analytics, and generative AI with human-in-the-loop review onto traditional workflows. Innovaccer's Comet platform, launched in 2025, is a good illustration — it automates over 70% of patient interactions and has cut call times by up to 38% for early adopters.
  4. Telehealth and digital-first patient engagement are structural tailwinds. As care shifts toward virtual and hybrid models, patients increasingly expect the same self-service convenience from healthcare that they get from banking or retail — digital scheduling, real-time cost estimates, and mobile-first registration.
  5. Regulation is both a driver and a design constraint. HIPAA, the No Surprises Act, and CMS interoperability rules in the U.S. — alongside GDPR and the European Health Data Space in the EU — are pushing providers toward digital tools that ensure cost transparency and secure data exchange. Compliance isn't optional, and that makes it a durable demand driver rather than a one-time push.

The Challenges Holding the Market Back

Growth in this market isn't friction-free. A few real headwinds stand out:

  • Fragmented systems and interoperability gaps. Even in North America — the largest regional market at a 44.18% share in 2024 — fragmented legacy systems and rising payer complexity remain persistent obstacles to seamless data exchange.
  • Regulatory compliance is a double-edged sword. The same rules driving adoption also raise the bar for vendors, who must ensure secure data handling and accurate integration or risk falling out of compliance.
  • Budget and procurement constraints, especially outside the U.S. In the UK, for example, limited NHS budgets and complex procurement processes are cited as real barriers to large-scale digital adoption, even as national reform initiatives create clear demand.
  • Vendor fragmentation. The market is described as slightly fragmented, with many software and service providers competing for share — good for buyers in the short term, but a source of consolidation risk for investors down the line.

Get the full picture. Download a free sample of the Patient Access Solutions Market Report from Grand View Research for detailed segmentation, company profiles, and regional forecasts through 2033.

Key Industry Players

The competitive landscape spans EHR incumbents, revenue-cycle specialists, and newer AI-native entrants. Leading companies in the space include:

  • Epic Systems Corporation
  • AGS Health LLC
  • IKS Health
  • Persistent Systems
  • Experian Information Solutions, Inc.
  • FinThrive
  • Oracle
  • PRIA Healthcare
  • GeneDx, LLC
  • Quadax, Inc.
  • Cognizant
  • R1
  • Waystar
  • Conifer Health Solutions
  • Infinx Healthcare
  • Engage
  • Annexus Health
  • Conduent Incorporated
  • Call 4 Health

Recent activity shows where competitive energy is concentrated. Relatient's March 2025 launch of Dash Direct, an open scheduling API platform, targets appointment automation across digital channels. SoundHound AI's 2024 partnership with MUSC Health deployed an AI voice agent integrated with Epic for round-the-clock patient engagement. And Infinx Healthcare's Intelligent Payer Mapping, launched in mid-2024, uses machine learning to standardize payer data and reduce manual errors in eligibility and prior authorization workflows. Across these moves, the pattern is consistent: incumbents and challengers alike are racing to embed AI into the front end of the revenue cycle.

Where the Investment Opportunity Sits

For investors and strategic acquirers evaluating this space, a few segments and geographies stand out based on the underlying report data:

  • Software over services — for now. Software held the largest share at 74.84% of the market in 2024, reflecting demand for core functionality like automated eligibility checks and denial prediction tools. But services are expected to grow fastest, as providers lean on external partners for implementation, integration, and ongoing support — a signal that managed-services and systems-integration plays may be underappreciated.
  • Integrated platforms are consolidating share. Integrated solutions held 78.60% of revenue in 2024 and are also expected to post the fastest growth, as providers consolidate vendors to reduce data silos and simplify EHR interoperability. Point solutions face real pressure to either integrate or get acquired.
  • Cloud deployment is the clear infrastructure bet. Cloud-based platforms are capturing share and growing fastest, driven by scalability and remote/telehealth compatibility — a familiar but reliable thesis for infrastructure-focused investors.
  • Prior authorization automation is the functionality to watch. While eligibility verification and coverage discovery hold the largest share today, prior authorization automation is projected to grow fastest, directly addressing one of the most cited pain points for providers.
  • Pharma and biopharma is an underpenetrated end-use segment. Healthcare providers remain the dominant end-use category, but pharmaceutical and biopharma companies are expected to grow fastest, as specialty therapy adherence and payer coordination become more complex and costly to manage manually.
  • Asia Pacific offers the highest growth trajectory. North America remains the largest market by revenue, but Asia Pacific is set to grow fastest, propelled by mobile-first patient engagement and government digital health initiatives such as India's Ayushman Bharat Digital Mission.

Taken together, the data points to a market where the biggest near-term opportunity may not be in the largest existing segment, but in the fastest-growing adjacent ones: prior authorization automation, cloud-native integrated platforms, services and implementation support, and expansion into pharma/biopharma and Asia Pacific markets.

Have specific investment or strategy questions? Speak directly with a Grand View Research analyst to get tailored insights on where the patient access solutions market is headed next.

North America Leads Real World Evidence Solutions Market in 2025

Healthcare decision-making is undergoing a quiet but profound shift. Clinical trials alone no longer tell the full story of how a drug or device performs — regulators, payers, and providers increasingly want to know what happens when a treatment meets real patients, in real settings, over real time. That demand is fueling rapid growth in the real world evidence solutions market:

  • Market size, 2025: USD 3.0 billion
  • Market estimate, 2026: USD 3.3 billion
  • Market forecast, 2033: USD 6.0 billion
  • Growth rate: CAGR of 9.1% from 2026 to 2033
  • Largest regional market: North America, holding a 44.1% revenue share in 2025
  • Fastest-growing regional market: Asia Pacific, through 2033

Behind these numbers lies a broader transformation: the healthcare industry is learning to turn scattered, messy, real-world data into structured, decision-grade evidence.

What's Driving the Real World Evidence Solutions Market

  1. Growing Regulatory Support and Policy Frameworks

Regulators are no longer treating real-world evidence as a supplementary nice-to-have — they're actively building it into approval and safety pathways. In December 2025, the U.S. FDA removed a longstanding requirement that RWE submitted in drug and device applications include identifiable individual patient data, opening the door for de-identified registries, claims, and EHR networks to be used in regulatory reviews. Around the same time, the UK's MHRA launched a pilot RWE Scientific Dialogue Programme under its 2024–27 Data Strategy, offering companies confidential guidance on evidence-generation strategy.

These moves matter because regulatory uncertainty has historically been one of the biggest barriers to RWE adoption. As agencies like the FDA, EMA, MHRA, and PMDA establish clearer standards for data quality and study design, pharmaceutical and biotech companies gain the confidence to invest further in RWE infrastructure.

  1. Rising Demand for Drug Safety and Post-Market Surveillance

As therapies grow more complex and regulatory scrutiny intensifies, the need to monitor drugs after they reach the market has never been greater. Adverse drug events are estimated to be the third leading cause of death in the U.S., contributing to between 250,000 and 300,000 deaths annually, according to the American Society of Pharmacovigilance. This sobering reality is pushing pharmaceutical companies and health systems toward RWE platforms capable of continuous safety monitoring and early detection of rare or long-term adverse effects.

  1. Explosive Growth in Real-World Data Volume

Health-related data is expanding at a compound annual rate of roughly 36%, flowing in from electronic health records, insurance claims, disease registries, wearables, and patient-reported outcomes. Advances in data integration and interoperability are letting RWE platforms convert this flood of raw information into insights that pharmaceutical companies, payers, and providers can actually act on.

  1. AI-Powered Analytics Unlocking New Value

Artificial intelligence is reshaping what's possible with real-world data. Vendors such as Saama, SAS Institute, Veradigm, and IQVIA are embedding AI and machine learning into their platforms to automate data curation, predictive modeling, and patient stratification. This is helping overcome one of the industry's toughest challenges: harmonizing fragmented, inconsistent datasets into unified, analysis-ready evidence — accelerating everything from drug development to value-based care initiatives.

Ready to Explore the Full Market Opportunity? Download a Free Sample Report — Get detailed market data, segment-level forecasts, and competitive insights on the Real World Evidence Solutions Market straight from Grand View Research's proprietary databases.

Where RWE Solutions Are Being Applied

Real-world evidence isn't a single-use tool — it's woven into multiple stages of the healthcare and life sciences value chain:

  • Drug Development & Approvals — the largest application segment, holding a 28.7% revenue share in 2025. RWE helps pharmaceutical companies and regulators streamline development timelines and support approval decisions, including for medical devices, where the FDA has issued specific guidance on using RWD in clearance decisions.
  • Reimbursement/Coverage and Regulatory Decision-Making — the fastest-growing application, as countries increasingly formalize RWE use across a product's full lifecycle, from pre-marketing activities to post-marketing label changes.
  • Post-Market Safety & Adverse Events Monitoring — critical given the scale of ADR-related harm, this application supports ongoing pharmacovigilance efforts.
  • Medical Device Development & Approvals — a growing use case as device makers integrate decades of clinical and real-world data into next-generation product design.

Key Industry Segments

By Component: The services segment dominates, accounting for 58.1% of revenue in 2025, reflecting strong demand from pharmaceutical, biotech, and provider organizations for expert-led RWE support. The data sets segment — spanning clinical settings data, claims data, pharmacy data, and patient-powered data — is set to grow significantly as organizations lean further into outcomes-based, evidence-driven research.

By Therapeutic Area: Oncology leads with a 23.1% share in 2025, driven by RWE's proven ability to lower clinical trial costs and speed regulatory approval in a field facing roughly 10 million new cancer cases and 9.7 million cancer-related deaths globally each year (GLOBOCAN, 2022). Cardiology is poised for strong growth, with roughly 64% of U.S. cardiologists expressing strong interest in RWE-focused educational programs, according to the American College of Cardiology Foundation.

By End Use: Healthcare companies — pharmaceutical, biopharmaceutical, and medical device firms — hold the largest revenue share, driven by the need to avoid costly drug recalls and validate real-world performance. Healthcare payers are expected to grow fastest, as RWE increasingly informs reimbursement decisions; notably, RWE has already been cited in nearly 16% of clinical findings payers use for specialty drug decisions.

By Region: North America leads with a 44.1% share, underpinned by strong regulatory backing and R&D investment, while Asia Pacific is forecast to grow fastest, propelled by government digitization initiatives and a rising base of contract research organizations in China and India.

The Road Ahead

With regulators actively lowering adoption barriers, data volumes climbing at scale, and AI transforming raw information into usable insight, the real world evidence solutions market is positioned for sustained, meaningful growth through 2033. Recent moves — from Thermo Fisher's January 2026 launch of the CoreVitas Obesity Registry to Datavant and AWS's cloud-based real-world data platform — signal an industry racing to make evidence generation faster, more secure, and more collaborative.

For pharmaceutical companies, payers, and healthcare providers alike, the message is clear: real-world evidence is no longer optional infrastructure. It's becoming the backbone of how healthcare decisions get made.

Speak to Our Research Analysts — Need a customized view of this market? Connect with our team to tailor the report to your region, segment, or strategic focus.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore our dedicated business services:

  • U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
  • Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
  • Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
  • Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
  • Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
  • Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
  • Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

Asia Pacific Set to Power Digital Pathology Market Expansion

Pathology, one of the last major diagnostic disciplines to fully digitize, is now firmly on that path. As hospitals, diagnostic labs, and life sciences companies look for faster turnaround times and more consistent diagnoses, digital pathology has moved from a niche research tool to a mainstream part of clinical and pharmaceutical workflows.

According to Grand View Research, the global digital pathology market was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 3.0 billion by 2033, expanding at a CAGR of 8.6% over the forecast period. North America led the market in 2025 with a 39.92% revenue share, while As      a Pacific is expected to post the fastest growth through 2033.

Here's a closer look at what's fueling this growth, the trends shaping the industry, the hurdles still standing in the way, and how different regions and segments are performing.

What's Driving the Market

  • Rising cancer burden and demand for precision diagnostics. The single biggest driver behind digital pathology adoption is the growing global cancer caseload. Pathologists need tools that can process tissue data quickly and help tailor therapies to individual patients, and digital pathology delivers on both fronts — accelerating diagnosis, improving accuracy, and supporting therapeutic decision-making. Academic research into deep learning models for image segmentation and classification in breast cancer diagnosis is one example of how far the underlying technology has advanced.
  • Demand for integrated, patient-centric healthcare systems. Health systems are increasingly moving toward integrated records that can be accessed across multiple facilities. This is pushing vendors toward more connected digital pathology offerings. A good example is the February 2025 expansion of the partnership between Charles River Laboratories and Deciphex, which is focused on building AI-powered image management tools for toxicologic pathology.
  • Growth in veterinary pathology. AI is making inroads into veterinary medicine just as it has in human diagnostics, particularly in preclinical drug research. Fewer regulatory restrictions around virtual slide-based veterinary diagnoses are accelerating adoption. Proscia's 2024 partnership with veterinary lab SpecialtyVETPATH to move toward a fully digital workflow illustrates this shift.
  • Wider healthcare IT adoption. Organizations are turning to digital pathology as part of broader healthcare IT investment aimed at cutting costs, easing resource bottlenecks, and enabling smoother collaboration and content sharing across teams and institutions.
  • AI-driven automation. AI is increasingly handling tasks that used to require manual review — like identifying regions of interest in tissue samples — cutting down on human error and freeing up pathologist time.

Key Trends to Watch

  • AI in digital pathology is becoming its own growth engine. A dedicated ecosystem of AI-native digital pathology companies — including Proscia, Aignostics, Aiforia, and Mindpeak — is emerging alongside traditional imaging vendors. Falling hardware costs, rising healthcare data volumes, and a wave of venture capital investment are all reinforcing this shift.
  • Drug discovery and precision medicine are opening new doors. Pharma and biotech companies are leaning on digital pathology for translational research, biomarker analysis, and companion diagnostics. Research commissioned by Proscia found that nearly 75% of surveyed life sciences organizations had already invested in digital pathology to strengthen their R&D capabilities. As spatial biology and genomics increasingly intersect with pathology imaging, this opportunity is only expanding.
  • Software leads, but devices are catching up fast. Software held the largest product share in 2025 at 42.88%, driven by platforms like Roche's uPath and Xybion's Pristima XD. But the device segment — scanners and slide management systems — is expected to grow even faster, powered by rising academic research activity and higher-resolution imaging needs.
  • Oncology remains the anchor use case, but cardiovascular is rising. Oncology accounted for 52.02% of revenue in 2025, unsurprising given that cancer remains one of the leading causes of death worldwide. Cardiovascular applications, however, are forecast to grow the fastest as AI-enabled tissue characterization tools mature.
  • A moderately consolidated, innovation-heavy market. The competitive landscape is described as slightly fragmented, with many vendors entering the space, high levels of partnership activity, and strong regulatory influence from bodies like the FDA and HIPAA. M&A activity is moderate — Fujifilm's 2023 acquisition of Inspirata's digital pathology business, including its Dynamyx system, is a notable example — while regional expansion is progressing steadily rather than explosively.

Want deeper data on vendors, regional forecasts, or segment-level opportunities? Explore the full market report and download a free sample at Grand View Research to inform your next strategic decision.

Challenges Facing the Market

Despite the strong growth outlook, the market isn't without friction points:

  • Workflow disruption during transition. Labs moving from traditional microscopy to digital workflows often face resistance from staff accustomed to established processes, along with the operational challenge of integrating new systems without slowing down diagnostic throughput.
  • Infrastructure and data management costs. Digitized slides generate enormous volumes of data, and building the scanning hardware and IT infrastructure to manage it requires significant upfront investment.
  • Regulatory complexity. Compliance with data integrity, security, and privacy regulations — including FDA requirements, HIPAA, and Clinical Laboratory Improvement Amendments — adds cost and complexity to deployment, especially for companies operating across multiple regions.
  • Illegitimate products in adjacent markets. In the veterinary pathology space specifically, counterfeit and unregistered veterinary medicines and compounded products pose safety risks and can undermine trust in the broader ecosystem of digital veterinary diagnostics.

The experience of IMP Diagnostics, a private pathology lab in Portugal, is a useful illustration of how labs are navigating these challenges — introducing barcode-based sample tracking, phasing in digitization gradually, and investing in staff training rather than attempting a disruptive, all-at-once rollout.

Regional Insights

  • North America led the market in 2025 with a 39.92% revenue share, supported by strong government backing for advanced pathology infrastructure, continuous R&D investment, and a concentration of major industry players. The U.S. leads within the region, helped by a mature healthcare infrastructure, high per-capita healthcare spending, and a growing number of FDA-cleared AI tools for cancer and skin lesion detection.
  • Europe is expected to grow at a solid pace, driven by high chronic disease prevalence and a dense network of diagnostic imaging centers. Government-backed research initiatives are playing a meaningful role — the European Institute of Biomedical Imaging Research alone has invested more than USD 66.84 million in biomedical imaging research over the past decade. The UK and Germany stand out as active national markets, each supported by clear digital pathology guidelines and rising cancer case volumes.
  • Asia Pacific is forecast to be the fastest-growing region through 2033, propelled by rapid digitalization, rising medical investment, and expanding digital imaging adoption across developing economies. China and Japan are key growth engines — China through partnerships like Aignostics' 2023 collaboration with Virchow Laboratories, and Japan through steady technological advancement and stronger early cancer detection initiatives.
  • Latin America is seeing meaningful growth as healthcare awareness improves, cancer prevalence rises, and local labs form partnerships with international digital pathology vendors.
  • Middle East & Africa remains an emerging market shaped largely by unmet pathology service needs, with telepathology — often supported by European collaborators — playing an outsized role in extending diagnostic access.

The Road Ahead

Digital pathology's trajectory over the next several years looks less like a niche technology upgrade and more like a fundamental shift in how tissue-based diagnosis happens — from slide to screen, and increasingly, from manual review to AI-assisted analysis. The convergence of imaging, AI, genomics, and precision medicine is creating opportunities well beyond traditional diagnostic labs, reaching into drug discovery, veterinary medicine, and remote care delivery.

For healthcare providers, diagnostic labs, and life sciences companies, the strategic question is no longer whether to adopt digital pathology, but how fast and in what sequence — balancing infrastructure investment, staff readiness, and regulatory compliance against the competitive cost of standing still.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Explore our dedicated business services:

  • U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
  • Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
  • Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
  • Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
  • Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
  • Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
  • Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

Healthcare Data Technology Market Report: Data Harmonization in Focus

Healthcare organizations are sitting on more data than ever before — electronic health records, connected devices, claims, imaging, and real-world evidence — and the race is on to turn that raw information into something usable. That race is fueling rapid growth in the healthcare data technology market, a space built around integrating, standardizing, securing, and monetizing health data at scale.

Here's a closer look at where the market stands today, what's driving it forward, and the roadblocks still standing in the way.

Key Market Facts

The global healthcare data technology market was valued at USD 3.1 billion in 2024 and is projected to grow from USD 4.0 billion in 2026 to USD 9.5 billion by 2033, expanding at a compound annual growth rate of 13.4% between 2025 and 2033. A few other numbers worth noting:

  • North America led the market in 2024, capturing a 46.5% revenue share, while Asia Pacific is on track to be the fastest-growing region going forward.
  • By technology, the health data integration and monetization segment dominated in 2024, holding more than 66.55% of total revenue, as providers work to unify EHRs, clinical trial data, and real-world evidence into single, usable pipelines.
  • The data harmonization and structuring segment, though smaller today, is expected to post the fastest growth rate of any segment over the forecast period, largely thanks to AI and NLP tools that can standardize messy, unstructured clinical data.
  • EHR adoption remains the backbone of this demand: as of December 2024, roughly 88% of U.S. office-based physicians were using an EMR/EHR system, with nearly 78% on a certified platform — a base that keeps generating more data to integrate and analyze.
  • The competitive landscape is notably fragmented, with dozens of established and emerging vendors — including IQVIA, Veeva Systems, Oracle (Cerner), Optum, Datavant, TriNetX, and Flatiron Health — all competing for share, which keeps innovation and partnership activity high.

Major Industry Trends

AI and advanced analytics are moving from pilot to production. Vendors are embedding generative AI and machine learning directly into data platforms rather than treating them as add-ons. Oracle's newly launched AI Data Platform, for example, is designed to help enterprises build AI-ready data lakes and deploy AI-driven applications directly on top of unified data.

Global harmonization initiatives are reshaping the data landscape. Governments and health systems are investing heavily in standardizing and connecting fragmented health records. Europe's Health Data Space regulation, formally adopted in 2025, sets a legally binding framework for cross-border health data access across the EU, covering both direct patient care and secondary research use. The UK has committed roughly £600 million toward a national Health Data Research Service, while Germany has launched a similarly ambitious medical informatics funding program — all aimed at making health data more accessible for research and care.

Interoperability is becoming a regulatory mandate, not just a best practice. In the U.S., federal regulators have intensified enforcement of information-blocking rules under the 21st Century Cures Act, pushing providers and vendors to make electronic health information more freely accessible and exchangeable.

Strategic partnerships and M&A are accelerating capability-building. Rather than building every capability in-house, companies are teaming up or acquiring their way into new strengths — from IQVIA and Veeva's long-term global partnership to streamline clinical trials, to Samsung's acquisition of digital health platform Xealth, to Commvault's move to acquire data security firm Satori Cyber to strengthen protections around AI training data.

Social determinants of health (SDOH) and real-world data are being folded into core platforms. Partnerships like HealthEdge and Unite Us embedding SDOH data into care management platforms reflect a broader shift toward more holistic, value-based data models that go beyond clinical records alone.

Emerging technologies are tackling harmonization at scale. Graph databases, federated learning frameworks, and AI-driven semantic mapping are increasingly used to link genomic, clinical, and multi-institutional datasets — enabling collaborative research without centralizing sensitive patient data.

Need data specific to your market or segment? This report can be tailored with additional countries, segments, or data points to match your exact research needs — with free customization available on purchase. Request Report Customization

Primary System Challenges

Data fragmentation across legacy systems. Many healthcare organizations still operate with claims, patient records, and lab results scattered across disconnected legacy systems, creating operational bottlenecks and slowing down everything from claims processing to clinical research.

Regulatory complexity and compliance costs. Stringent privacy and security frameworks — HIPAA, GDPR, and a growing patchwork of regional health data governance rules — demand robust compliance and audit capabilities. While these regulations push innovation in secure data management, they also add real implementation complexity and cost for both providers and vendors.

Interoperability gaps between platforms. Despite widespread EHR adoption, getting different systems to talk to each other in a standardized way (HL7/FHIR and beyond) remains a persistent hurdle, particularly for organizations trying to merge imaging, genomic, and unstructured clinical data.

Balancing data monetization with privacy. As organizations look to unlock value from health data — through analytics, research partnerships, or licensing — they must simultaneously protect patient privacy, driving demand for de-identification, pseudonymization, and governance tools that can slow down time-to-insight.

Scalability under growing data volumes. As data volume and variety expand (from wearables, genomics, and real-world evidence), organizations need cloud-native, auto-scaling infrastructure — a shift that isn't trivial for institutions still running on manual or semi-automated processes.

Regional disparities in infrastructure and investment. While North America and Europe are pushing ahead with major national data initiatives, regions like Latin America and parts of MEA are still working to modernize foundational health data infrastructure, creating uneven adoption rates globally.

The bigger picture: healthcare data technology is no longer a back-office IT concern — it's becoming central to how care gets delivered, how research gets funded, and how health systems compete. Organizations that solve for interoperability, compliance, and scalability today will be the ones best positioned to capture value as the market roughly triples in size by 2033.

Want the Full Picture? See who's leading the market. Get access to detailed profiles of the key players shaping the healthcare data technology space — including IQVIA, Veeva Systems, Oracle, Optum, Datavant, and more — along with their strategies, partnerships, and market positioning. Explore Key Players

Explore our dedicated business services:

  • U.S. Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
  • Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
  • Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
  • Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
  • Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
  • Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
  • Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.

Data Encryption Market to Hit USD 37.2 Billion by 2033, Report Says

Data is now the most valuable — and most attacked — asset most organizations own. As cloud adoption accelerates, AI workloads multiply, and regulators tighten data protection rules, encryption has moved from a "nice to have" security control to a foundational layer of enterprise cybersecurity strategy.

The global data encryption market reflects this shift:

  • 2025 market size: USD 15.2 billion
  • 2026 market estimate: USD 16.9 billion
  • 2033 market forecast: USD 37.2 billion
  • CAGR (2026–2033): 11.9%

That growth trajectory isn't just about bigger budgets — it's a signal of how central encryption has become to digital trust, compliance, and business continuity.

Let's break down who's leading the space, where growth is concentrated geographically, and what's fueling this expansion.

Prominent Market Competitors

The data encryption industry is moderately fragmented, bringing together established cybersecurity giants, cloud hyperscalers, and specialized encryption vendors. Some of the most prominent players shaping the competitive landscape include:

  • Amazon Web Services
  • Broadcom
  • Check Point Software Technologies
  • Cisco
  • Dell Technologies
  • Entrust
  • Fortinet
  • Google
  • IBM
  • Microsoft
  • Oracle
  • Palo Alto Networks
  • Sophos
  • Thales
  • Trend Micro

Within this group, a useful way to think about competitive positioning is to split the field into two tiers:

Mature players — including Microsoft, IBM, Thales, Cisco, and Oracle — tend to focus on integrated encryption platforms spanning cloud, endpoint, database, and hybrid IT environments. These companies are investing heavily in AI-driven security and quantum-safe cryptography, backed by large enterprise customer bases and established regulatory credibility. The trade-off: broad product portfolios can introduce integration complexity, slower deployment cycles, and higher costs compared to more focused vendors.

Emerging players — such as Trend Micro, Entrust, and Sophos — are expanding cloud-native encryption and zero-trust capabilities through acquisitions and platform integration, with growing emphasis on AI-powered threat detection and encryption solutions tailored to SMEs. These vendors often move faster and offer more competitive, flexible pricing, though they generally have less penetration in highly regulated, large-enterprise environments and rely more heavily on partner ecosystems to scale globally.

Recent moves underscore where the competitive energy is heading. In March 2026, Broadcom rolled out a post-quantum cryptography-safe in-flight network encryption solution built on its Emulex SecureHBA technology, designed to protect data moving across server-to-storage networks against future quantum threats. A few months earlier, in July 2025, Fortinet introduced quantum-safe capabilities into FortiOS, combining post-quantum cryptography with quantum key distribution to guard against "harvest-now, decrypt-later" attacks. Both moves reflect a broader industry pivot: encryption vendors are racing to future-proof their offerings against quantum computing risk well ahead of it becoming a mainstream threat.

Want deeper insights into where the data encryption market is headed? Download a free market research sample to explore detailed segmentation, forecasts, and competitive benchmarking.

Regional Overview

Encryption adoption isn't uniform across the globe — it tracks closely with regulatory pressure, cloud maturity, and digital infrastructure investment.

North America dominated the market in 2025, commanding a 39.6% revenue share. This leadership stems from large-scale encryption deployment across cloud-first architectures by hyperscalers and enterprise SaaS providers, along with early enterprise experimentation with post-quantum cryptography in regulated sectors. Financial institutions have accelerated adoption of field-level and tokenization-based encryption in response to tightening compliance standards like PCI DSS 4.0, while government, defense, and healthcare organizations continue expanding encryption around hardware security modules and HIPAA-driven EHR protections. The U.S. leads the region, propelled by post-quantum readiness programs, zero-trust architecture rollouts across critical infrastructure, and growing use of confidential computing to protect data-in-use.

Asia Pacific is the fastest-growing region heading into 2033. Rapid expansion of digital payment ecosystems and mobile-first financial services across India, China, and Southeast Asia is a major catalyst, compounded by stricter data localization laws such as China's Cybersecurity Law and India's Digital Personal Data Protection framework. The region is also seeing strong encryption uptake tied to 5G-enabled IoT deployments and connected manufacturing. China's market is shaped heavily by data sovereignty mandates and state-owned enterprise adoption in banking, telecom, and energy; Japan is leaning into quantum-safe cryptography amid rising cyber-espionage concerns; and India's growth is fueled by UPI-driven digital payments and the Digital Personal Data Protection Act.

Europe is set for steady growth, anchored by strict regulatory frameworks like GDPR and the EU Data Act, alongside rising sovereign cloud initiatives in countries like Germany and France. The UK is seeing strong encryption demand in banking and fintech tied to open banking APIs, while Germany's growth is closely linked to securing connected vehicle data and industrial IoT within its manufacturing base.

Key Industry Drivers

Escalating cybersecurity threats and regulatory pressure. Organizations are under growing pressure to defend against ransomware, data breaches, and increasingly sophisticated cyberattacks — all while navigating a thickening web of data privacy regulations. As enterprises lean further into cloud computing, AI, and broader digital transformation, demand for advanced encryption, centralized key management, and secure data processing is rising sharply across BFSI, healthcare, government, and telecom. A good example: in October 2025, NTT DATA partnered with Fortanix to launch a Cryptography-as-a-Service solution aimed at securing AI, multicloud, and hybrid environments while preparing enterprises for post-quantum risks — illustrating how seriously the industry is now treating quantum preparedness.

The shift to cloud-native, API-driven encryption. Enterprises are increasingly relying on built-in encryption capabilities from hyperscalers rather than standalone, on-premises tools. This is reshaping vendor strategy toward automated, policy-based encryption designed for cloud-native architectures — while customer-controlled key models, like the Customer-Managed Encryption Keys Zilliz introduced on Zilliz Cloud in March 2026, are giving enterprises more transparency and ownership over their own security.

Encryption as part of a broader data security strategy. Rather than functioning as an isolated tool, encryption is increasingly embedded into wider data protection ecosystems that include discovery, classification, and security posture management. Quantum-resistant encryption, zero-trust architecture, and AI-driven security analytics are becoming standard components of next-generation offerings.

One constraint worth noting: performance overhead remains a real barrier. Advanced encryption can introduce latency in high-volume, real-time environments — a meaningful concern for BFSI, healthcare, telecom, and e-commerce companies running large-scale transactional workloads. As a result, some organizations still limit encryption to select workloads rather than deploying it enterprise-wide, which continues to temper the pace of full-scale adoption.

The Road Ahead

The data encryption market's trajectory — from USD 15.2 billion in 2025 toward USD 37.2 billion by 2033 — reflects a fundamental reality: as data becomes more distributed, more valuable, and more regulated, encryption is no longer optional infrastructure. It's becoming the backbone of enterprise digital trust.

For organizations navigating vendor selection, regional expansion, or compliance strategy, understanding this competitive and regional landscape is the first step toward building an encryption strategy that scales with the business — not against it.

Ready to strengthen your data protection strategy? Talk to a cybersecurity solutions expert today to evaluate which encryption approach fits your infrastructure and compliance needs.

Edge Computing In Healthcare Market Size to Hit $24.8B by 2033

Hospitals and clinics generate an enormous, constant stream of patient data — from bedside monitors and imaging scanners to wearables and infusion pumps. Sending all of that to a distant cloud server for processing introduces delay, and in critical care, delay can cost lives. That's the core problem edge computing solves: it moves data processing closer to where the data is created, right at the hospital, the clinic, or even the patient's wrist.

According to Grand View Research, the global edge computing in healthcare market was valued at $5.8 billion in 2025 and is projected to grow from $7.0 billion in 2026 to $24.8 billion by 2033, at a CAGR of 19.8%. That's roughly a fourfold increase in under a decade — a clear signal that healthcare organizations see edge infrastructure as essential, not optional, going forward.

Here's a closer look at why the technology matters, how it's actually being used, and which segments and regions are leading the charge.

Core Benefits of Edge Computing in Healthcare

Faster, real-time decision-making. By processing data locally instead of round-tripping it to a centralized cloud, edge systems cut the latency that can slow down clinical response. In an ICU or emergency room, that speed difference can directly affect patient outcomes.

Reduced dependence on network connectivity. Because analysis happens on-site or on-device, edge computing keeps critical systems running even when internet connectivity is unstable — a major advantage for rural clinics, ambulances, and home-care settings.

Support for AI at the point of care. AI-driven diagnostics, predictive analytics, and clinical decision support tools need to crunch data fast. Running these algorithms on edge hardware, closer to the devices generating the data, reduces the load on centralized infrastructure while speeding up results.

Stronger data privacy and security posture. Keeping sensitive patient data local, rather than constantly shuttling it to the cloud, can help healthcare organizations manage compliance with regulations like HIPAA in the U.S. and GDPR in Europe.

Operational efficiency at scale. Edge-enabled systems support automated alerts, workflow coordination, and predictive maintenance across hospital departments — reducing administrative bottlenecks and freeing up clinical staff.

Want the full market picture? Download the complete market report for detailed segment forecasts, regional breakdowns, and competitive analysis to inform your next strategic decision.

Common Uses of Edge Computing in Healthcare

  • Telehealth and remote patient monitoring — processing data from home monitoring devices and wearables in real time to flag issues in chronic disease and high-risk patients before they escalate.
  • Diagnostics and medical imaging — running AI-assisted image analysis locally to speed up radiology and diagnostic workflows.
  • Robotic and AI-assisted surgery — supporting the ultra-low latency required for precision-guided surgical robotics.
  • Connected ambulances and emergency care — enabling paramedics to transmit and process vital data before a patient even reaches the hospital.
  • Clinical workflow management — powering real-time alert systems, staff coordination tools, and predictive operational analytics in busy care settings.
  • Smart wearables and insulin delivery — enabling on-device, biosensor-driven dosing decisions without needing constant connectivity, supporting more personalized, ambulatory care.

Market Segmentation and Dominance

Grand View Research breaks the market down by component, application, end use, and region — and a few clear leaders stand out.

By component: Hardware — edge servers, gateways, routers, sensors, and connected medical devices — held the largest market share at 53.9% in 2025, driven by hospitals' reliance on physical infrastructure for real-time processing. However, software and services are catching up fast, expected to be the fastest-growing component as providers invest more in analytics platforms, device management, and integration support.

By application: Telehealth and remote patient monitoring led with a 29.9% revenue share in 2025, and this segment is also forecast to grow the fastest — a reflection of how central remote and decentralized care has become to modern healthcare delivery.

By end use: Hospitals accounted for the largest share, at 42.9% of the market in 2025, thanks to the sheer volume of patient and operational data generated in hospital settings. Meanwhile, long-term care and homecare settings are projected to grow at the fastest rate, as remote monitoring technology extends care beyond hospital walls.

By region: North America dominated with a 55.9% revenue share in 2025, backed by mature healthcare IT infrastructure and strong digital health investment, with the U.S. as the top individual country market. Asia Pacific, meanwhile, is set to be the fastest-growing region through 2033, fueled by expanding digital healthcare infrastructure, 5G rollout, and rising government investment in smart hospital initiatives across countries like China and India.

Key players shaping this space include Huawei Technologies, Advantech, Koninklijke Philips, Cognizant, NVIDIA, IBM, Microsoft, and Amazon Web Services — companies bringing everything from edge AI chips to cloud-integrated healthcare software platforms to market.

The Bottom Line

Edge computing is quickly becoming foundational infrastructure for modern healthcare — not a nice-to-have, but the backbone that makes real-time monitoring, AI-assisted diagnostics, and decentralized care delivery possible. With the market on track to grow from $7.0 billion in 2026 to $24.8 billion by 2033, organizations that invest early in edge-ready infrastructure will be best positioned to deliver faster, safer, and more connected patient care.

Ready to bring edge computing into your healthcare organization? Talk to our team about assessing your infrastructure readiness and building a roadmap for edge-enabled patient monitoring, diagnostics, and clinical workflows.

Marine Hybrid Propulsion Market Analysis by Vessel Type

The maritime industry is in the middle of a major power shift. As shipowners face mounting pressure to cut fuel bills, reduce emissions, and meet tightening international regulations, hybrid propulsion has emerged as one of the most practical bridges between traditional diesel engines and a fully electric future.

According to Grand View Research, the global marine hybrid propulsion market was valued at USD 8.1 billion in 2025 and is projected to climb from USD 9.0 billion in 2026 to USD 18.7 billion by 2033, growing at a CAGR of 11.1% during the forecast period. That's more than double in less than a decade — a clear signal that hybrid systems are moving from niche pilot projects to mainstream fleet strategy.

Why Hybrid Propulsion Is Gaining Momentum

Hybrid propulsion systems combine conventional combustion engines with electric motors and energy storage, letting vessels switch between or blend power sources depending on operating conditions. Instead of running a diesel engine at inefficient partial loads, hybrid setups let engines operate closer to their optimal output while batteries handle low-demand situations like maneuvering, standby, or port operations.

This flexibility translates directly into lower fuel consumption, reduced emissions, quieter operations, and lower maintenance costs — all of which matter enormously to an industry facing both economic pressure and regulatory scrutiny from bodies like the International Maritime Organization (IMO).

Market Segmentation: Where the Growth Is Concentrated

By Propulsion Type

Parallel hybrid propulsion systems lead the market, commanding over 55.9% of global revenue in 2025. These systems let mechanical and electric power sources work together within the same drivetrain, offering an easier upgrade path than a full engine overhaul while still delivering strong efficiency gains. Diesel-electric hybrid systems are the fastest-rising alternative, particularly well-suited to vessels with highly variable load profiles such as offshore support vessels, ferries, and cruise ships.

By Installation

Retrofit installations dominate, accounting for over 65% of market share. Upgrading an existing vessel is far cheaper than building a new one, and retrofits let operators meet emissions standards on tighter timelines with minimal fleet disruption. That said, newbuild installations are gaining traction fast, as shipbuilders increasingly design hybrid architecture into vessels from the outset — improving space utilization, reliability, and lifecycle costs.

By Power Rating

The 1 MW–5 MW segment leads, capturing over 48% of revenue in 2025, thanks to its fit with medium-sized commercial and offshore vessels. Meanwhile, the above 5 MW segment is the one to watch — cruise ships, naval vessels, and large commercial ships with continuous high-power demands are increasingly turning to hybrid systems to cut fuel use without sacrificing performance.

By Vessel Type

Offshore Support Vessels (OSVs) are the current leaders, holding over 33% of revenue share, largely because their operating profile — dynamic positioning, standby, transit — is practically tailor-made for hybrid efficiency gains. Naval and defense vessels represent the fastest-growing vessel category, driven by the strategic value of electric-mode "stealth" operation, which reduces acoustic and thermal signatures during sensitive missions.

By Application

Commercial shipping is the largest application segment at over 43% share, reflecting the sheer scale of the global merchant fleet and its need for cost-efficient, long-haul operations. The defense segment is expected to grow fastest, propelled by naval modernization programs and the premium placed on quiet, fuel-flexible vessels for extended missions.

By Region

Asia-Pacific dominates the global market with a 35.3% revenue share in 2025, anchored by shipbuilding powerhouses China, South Korea, and Japan. China alone leads the regional market on the strength of its shipyard density and aggressive green-shipping policy push. North America is projected to be the fastest-growing region through 2033, while Europe — led by Norway, Finland, and the Netherlands — continues to set the pace on regulatory ambition and early adoption of hybrid and fully electric ferries.

Ready to act on this data? Want the full market breakdown? Get the complete segmentation, competitive landscape, and country-level forecasts in the detailed industry report. Download the Free Sample Report

Core Growth Drivers

  • Tightening emissions regulation. IMO standards and regional clean-shipping mandates are pushing operators toward lower-emission propulsion, with retrofit hybrid solutions offering a fast compliance route.
  • Fuel cost pressure. Optimized load management directly cuts fuel spend, a major line item for commercial and offshore operators.
  • Technology maturity. Advances in energy storage, smart power management, automation, and digital monitoring are making hybrid systems more reliable and easier to integrate.
  • Fleet modernization and naval investment. Naval modernization programs and next-generation warship development are accelerating hybrid adoption in defense fleets, valuing both stealth and range benefits.
  • Green shipbuilding momentum. Growing global maritime trade and investment in energy-efficient newbuilds are expanding the addressable market beyond retrofits alone.

Where the Opportunities Lie

Vendors and investors have several clear openings:

  1. Retrofit-focused solutions for aging commercial and offshore fleets that need fast, low-disruption compliance upgrades.
  2. High-power hybrid systems (above 5 MW) tailored to cruise, naval, and large commercial vessels — a segment still in its early growth curve.
  3. Naval and defense propulsion, where the value proposition extends beyond efficiency to strategic capability.
  4. Regional expansion in North America, currently the fastest-growing market, and continued deepening in Asia-Pacific's shipbuilding hubs.
  5. Integrated digital power management, pairing hybrid hardware with smart monitoring and automation platforms to capture recurring service revenue.

Leading players shaping this landscape include ABB Ltd., Wärtsilä Corporation, Rolls-Royce Holdings plc, MAN Energy Solutions, Siemens Energy AG, Kongsberg Gruppen, GE Marine, Volvo Penta, Caterpillar Inc., and BAE Systems — each investing in hybrid propulsion architecture, energy storage, and power management technology to stay ahead of a fast-moving market.

The Bottom Line

Marine hybrid propulsion has moved well past the experimental stage. With an 11.1% CAGR and the market more than doubling by 2033, this is a sector where regulatory necessity, cost pressure, and technological readiness are all pulling in the same direction. Whether the entry point is a retrofit for an aging commercial fleet or a next-generation naval platform, the opportunity window is wide open — but it will favor those who move early on both technology partnerships and regional positioning.

Need insights tailored to your business? Customize this report with the regions, segments, or data points that matter most to your strategy — at no extra cost. Request a Custom Report

Construction Management Software Market Share, Trends & Forecast

Construction has long been one of the slowest industries to digitize — but that's changing fast. As projects grow more complex, budgets tighten, and stakeholders demand real-time visibility, construction firms are turning to purpose-built software to keep everything on track. According to Grand View Research, this shift is fueling substantial, sustained growth in the construction management software market over the next decade.

Market Overview and Projections

The global construction management software market was valued at USD 7.7 billion in 2025 and is projected to climb to USD 8.3 billion in 2026, eventually reaching USD 16.4 billion by 2033. That translates to a robust CAGR of 10.2% between 2026 and 2033 — meaning the market is set to more than double in less than a decade.

A few standout figures from the report:

  • New construction projects captured the largest share of revenue in 2025, at 57.8%, reflecting the sheer volume of residential, commercial, and infrastructure builds underway globally.
  • Maintenance and facility upgrades is the fastest-growing project type category, as organizations increasingly invest in extending asset lifecycles.
  • Cloud deployment dominated in 2025, while on-premise solutions are expected to see meaningful growth among enterprises with strict data governance needs.
  • Large enterprises led adoption in 2025, but SMEs are projected to grow fastest as affordable, subscription-based tools lower the barrier to entry.
  • Project management and scheduling remains the top application by revenue, while field service management is the fastest-growing application segment.

Drivers and Trends Shaping the Market

Several forces are converging to push construction firms toward digital management platforms:

Rising project complexity. Governments and private developers are pouring capital into residential, commercial, and infrastructure projects worldwide. Coordinating contractors, subcontractors, architects, and clients across these larger, more intricate builds has made centralized software tools less of a luxury and more of a necessity.

Demand for unified data and visibility. With so many stakeholders involved in a single project, fragmented communication leads to costly errors. Construction management platforms provide a shared, real-time view of progress, budgets, and documentation — reducing miscommunication and improving decision-making.

Cost and risk pressures. Rising material and labor costs are pushing firms to prioritize tools that support accurate budgeting, cost estimation, and financial forecasting, helping them avoid overruns and protect margins.

Regulatory and safety compliance. Tightening safety and compliance regulations are driving demand for software that can track documentation, manage protocols, and simplify audits and inspections.

Technology convergence. The integration of Building Information Modeling (BIM), artificial intelligence, and data analytics is transforming what construction software can do — enabling predictive insights, smarter design coordination, and more informed decision-making across the project lifecycle.

Cloud and mobile adoption. The growing use of mobile devices on job sites is accelerating the shift to cloud-based platforms that support instant updates, remote monitoring, and real-time collaboration between office and field teams.

Need Data Tailored to Your Business? Every business has different priorities — whether that's a specific country, segment, or competitive angle. Grand View Research offers report customization, so you get the data that matters most to your strategy. Request Your Customized Report

Major Industry Players

The market features a mix of established enterprise software giants and specialized construction-tech firms. Prominent companies profiled in the report include:

  • Procore Technologies, Inc. — a cloud-based platform connecting stakeholders across the entire construction lifecycle, used across more than 160 countries.
  • Autodesk, Inc. — known for its Autodesk Construction Cloud suite, including Autodesk Build, BIM Collaborate, and Takeoff, offering end-to-end digital solutions for the AEC industry.
  • Trimble Inc.
  • Oracle
  • Sage Group plc
  • Bluebeam
  • CMiC
  • CoConstruct (A Buildertrend Company)
  • ConstructConnect
  • Fieldwire by Hilti
  • Jonas Construction Software Inc.
  • Nemetschek Group
  • PlanRadar
  • RIB Software GmbH
  • STACK Construction Technologies

Recent moves underline how competitive this space has become. In early 2026, Autodesk rolled out more than 40 updates to its Construction Cloud platform, strengthening data management, access control, and AI-powered assistance features. Earlier, Autodesk had also moved to acquire Payapps to bolster payment and compliance capabilities within its ecosystem — a sign that platform consolidation and feature expansion are key competitive strategies in this market.

Regional Leadership

North America led the global market in 2025, holding a 31.9% revenue share. This dominance stems from early adoption of digital construction technologies, a strong base of established software vendors, and heavy investment in infrastructure and commercial construction. Widespread cloud adoption, growing BIM integration, and strict safety and compliance regulations continue to reinforce the region's leadership — with the U.S. market benefiting further from large-scale government infrastructure initiatives and rising demand for AI-driven project analytics.

Asia Pacific, however, is the fastest-growing region for the forecast period. Rapid urbanization, expanding smart city initiatives, and large-scale infrastructure and real estate investment across markets like India and Southeast Asia are driving momentum. China holds the largest country-level share in the region, supported by its focus on transportation networks, urban housing, and growing adoption of prefabrication and modular construction techniques.

Europe is seeing steady growth as well, propelled by sustainability mandates, green building initiatives, and digital twin adoption — with the UK standing out due to BIM mandates for public sector projects and rising renovation activity across aging infrastructure.

Explore the full regional and country-level breakdown — including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa — to identify where demand is accelerating fastest. Explore the Regional Outlook

Inside the Personalized Nutrition Platform Market's $1.93B Trajectory

Nutrition advice used to come in one size: a food pyramid, a generic calorie target, a pamphlet from the doctor's office. That era is fading fast. A new class of digital platforms is turning genetics, microbiome data, wearables, and lab results into individualized diet and supplement guidance — and the market built around this shift is scaling quickly.

Market Size & Key Metrics

The global personalized nutrition platform market is on a clear upward trajectory:

  • 2024 Market Size: USD 930.0 Million
  • 2026 Market Estimate: USD 1,067.7 Million
  • 2033 Market Forecast: USD 1,926.6 Million
  • CAGR (2025–2033):6%

In short — the market is set to more than double in under a decade, driven by rising demand for data-backed, individualized dietary guidance.

A few numbers frame the shape of this growth:

  • North America led the market in 2024 with a 40.0% revenue share, while Asia Pacific is on track to be the fastest-growing region through the forecast period.
  • Software/Platform offerings dominated with over 83.0% share in 2024, underscoring how central AI-driven engines and apps are to this space — though the services segment (dietitian consultations, onboarding, custom plan creation) is expected to grow fastest as digital tools pair with human expertise.
  • By delivery model, B2C (direct-to-consumer) captured the largest share at 57.13% in 2024, reflecting consumers' growing comfort with subscription apps and at-home testing kits. B2B2C/channel partnerships — platforms distributed through insurers, employers, and gyms — are expected to grow the fastest.
  • Weight management & metabolic health was the leading application in 2024, fueled by rising obesity rates and the wave of consumer interest tied to GLP-1 medications.
  • Healthcare professionals & clinics represented the largest end-use segment, while employers/corporate wellness is projected to post the fastest CAGR as companies fold nutrition coaching into workplace health programs.

The macro backdrop matters here too: the World Obesity Federation estimates roughly 3 billion people globally live with overweight or obesity, and WHO figures from 2024 point to 35 million children under five being overweight. That health burden is a direct tailwind for platforms promising tailored, data-backed dietary guidance instead of generic advice.

Curious which regions are set to drive the next wave of growth? Dive into region-by-region trends — from North America's current dominance to Asia Pacific's fast-growing adoption curve — to see where the biggest opportunities lie.

Core Tech & Testing Segments

What actually powers "personalization" in these platforms? A convergence of testing modalities and software capability:

  • Genetic testing — DNA-based insights into metabolism, nutrient processing, and predispositions, popularized by players like DNAfit.
  • Microbiome analysis — gut health profiling that informs food and supplement recommendations, a core differentiator for companies like ZOE and Viome Life Sciences.
  • Biomarker and lab-based testing — bloodwork-driven plans are gaining traction; for example, a 2025 U.S. membership program built its guidance around more than 70 biomarkers, and an AI lab-interpretation platform recently added biomarker-based meal planning tied directly to patients' bloodwork.
  • Wearables and mobile integration — real-time biometric and activity data feeding into recommendation engines, enabling continuous rather than static personalization.
  • AI and machine learning — the connective tissue across all of the above. AI is increasingly used to translate genetic, microbiome, lifestyle, and biometric inputs into meal plans, supplement blends, and nutrient-dense (rather than purely calorie-focused) food guidance. Recent examples include an AI-powered nutrient-categorization tool for cardiometabolic programs and customizable, AI-recommended supplement formulas built from a large library of individual nutrients.
  • Interoperability — integration with electronic health records and health apps is becoming a differentiator, especially for platforms selling into clinical settings.

Together, software/platform technology accounted for over 83% of 2024 revenue, making it clear that even service-heavy business models are built on a digital, data-processing backbone.

Market Challenges & Friction Points

Despite the momentum, several friction points shape how this market develops:

  • Regulatory complexity. Platforms handling sensitive health and genetic data must navigate FDA guidance, HIPAA, and regional data protection rules simultaneously. Evolving standards around health claims and AI-generated recommendations add another layer of compliance burden, and the report characterizes regulatory impact on the industry as high.
  • Market fragmentation. The competitive landscape is described as highly fragmented, with many small and large players competing for share — a dynamic that intensifies price and feature competition, particularly among smaller entrants trying to sustain their position.
  • Trust and data privacy. Because these platforms depend on deeply personal inputs — genetic profiles, biomarkers, dietary habits — consumer trust in how that data is stored, shared, and used is a persistent hurdle to adoption, especially as AI plays a larger role in generating recommendations.
  • Balancing automation with human guidance. Fully automated software drives scale, but the fastest-growing services segment signals that many consumers still want a dietitian or nutritionist in the loop — a tension platforms must resolve in their product design.
  • Regional expansion pace. While innovation and partnership activity in the industry are high, regional expansion is only moderate, suggesting that scaling personalized nutrition models across new geographies — with different regulatory regimes, health infrastructure, and consumer habits — remains a slower, more deliberate process.

Personalized nutrition is no longer a niche wellness trend — it's becoming an expected layer of digital health, sports performance, and corporate wellness strategy. The next phase of growth will likely hinge on how well platforms can pair AI-scale personalization with the regulatory trust and human touch that health-related decisions still demand.

Want to know how the market's leading players are positioning themselves? Explore competitive strategies, partnerships, and product launches from companies like ZOE, Viome, Nestlé, and HealthifyMe shaping the personalized nutrition platform landscape.

Precision Medicine Software Market: Top Growth Drivers Explained

Precision medicine software has moved from a niche research tool to a core piece of modern healthcare infrastructure. As genomic sequencing gets cheaper and hospitals lean harder on data-driven care, the software that turns raw genetic and clinical data into actionable insight is becoming indispensable.

The numbers back this up. The global precision medicine software market was valued at USD 2.1 billion in 2024 and is projected to reach USD 5.7 billion by 2033, growing at a CAGR of 11.8% from 2025 to 2033. North America led the pack in 2024 with a 40.4% share, while Asia Pacific is emerging as the fastest-growing region.

Here's a closer look at who's building this market, what's holding it back, what's pushing it forward, and where it's headed.

Top Industry Vendors & Solutions

The precision medicine software space is fragmented but active, with established diagnostics giants sitting alongside fast-moving AI-native platforms. Leading companies shaping the competitive landscape include:

  • Tempus AI, Inc. — known for its multimodal data platform combining genomic, clinical, and imaging data for oncology and beyond
  • IQVIA — a major force in healthcare data, analytics, and clinical research technology
  • SOPHiA GENETICS — a genomic and clinical data analysis platform used across hospitals and labs
  • Foundation Medicine, Inc. — a specialist in companion diagnostics and genomic profiling
  • Genedata AG — enterprise software for biopharma R&D and precision medicine workflows
  • Owkin, Inc. — AI-driven drug discovery and biomarker research
  • PierianDx, GenomOncology LLC, Inspirata, Inc., Genomind, Precision Medicine Group, LLC., Siemens, Qserve, and OSP round out a field where innovation, partnerships, and regulatory approval all matter as much as raw technology.

One notable consolidation: Syapse was acquired by N-Power in January 2025. Partnerships are also reshaping the space — in April 2025, Illumina and Tempus AI announced a collaboration to combine Illumina's sequencing technology with Tempus's data platform, aiming to build new genomic algorithms and speed up clinical adoption of next-generation sequencing tests. Similarly, GenomOncology partnered with Pillar Biosciences in February 2025 to pair clinical decision support software with targeted NGS panels for faster, more personalized cancer treatment guidance.

Across these vendors, a common thread stands out: AI and machine learning are no longer add-ons but the core differentiator. In fact, the AI/ML models and generative AI technology segment already commands the largest share of the market — 36.67% in 2024 — as companies build tools that can interpret complex genomic and clinical datasets and recommend treatment paths.

Ready to explore the full market data? Download a free sample of the Precision Medicine Software Market report to see detailed segment forecasts, regional breakdowns, and vendor positioning.

Primary Obstacles to Widespread Adoption

Despite strong momentum, several barriers are slowing broader rollout of precision medicine software:

  • Regulatory complexity. Approvals such as FDA clearance and CE marking are essential for building trust with providers and payers, but the certification process is rigorous and can delay time-to-market for new tools.
  • Data privacy and cross-border restrictions. In Europe particularly, strict frameworks like GDPR add friction, alongside high implementation costs and inconsistent reimbursement policies across different countries.
  • Legacy infrastructure and control concerns. Some healthcare organizations still favor on-premise deployment because they want direct control over sensitive genomic and clinical data and need to integrate with older IT systems — even though this can mean slower scalability compared with cloud alternatives.
  • Data volume and storage demands. Genomic datasets are massive, with projections suggesting human genome storage needs could reach between 2 and 40 exabytes by 2025 — a scaling challenge for any platform handling this data.
  • Interoperability gaps. Getting genomic platforms, electronic health records, laboratories, and clinical systems to exchange data seamlessly (via standards like FHIR and HL7) remains an ongoing technical hurdle, though it's also becoming a growth opportunity for vendors who solve it well.

Key Drivers

Several forces are pushing the market forward at a steady clip:

  • Falling sequencing costs. What cost close to USD 100 million per genome in the early 2000s can now be done for under USD 500, turning sequencing from a research luxury into routine clinical practice.
  • Government and institutional investment. Programs worldwide are funding genomics infrastructure — from Canada's roughly USD 143.69 million Canadian Precision Health Initiative to India's Phenome India Project and the UK's Advancing Precision Medicine funding round — all generating demand for the software that manages this data.
  • Rising demand for personalized, targeted therapies. As oncology and rare disease treatment increasingly rely on biomarker-driven approaches, software for clinical decision support and companion diagnostics becomes essential rather than optional.
  • Growth of decentralized trials and real-world evidence. Clinical research is shifting toward models that depend on robust data platforms to manage distributed, real-time information.
  • Cloud adoption. The cloud-based deployment segment held 70.70% of revenue share in 2024 thanks to scalability, remote accessibility, faster deployment of AI analytics, and support for multi-institutional collaboration.

Market Trends

A few clear patterns are defining where the market goes next:

  1. AI is now central, not peripheral. Machine learning and generative AI are being woven into biomarker identification, therapy response prediction, and patient stratification — reshaping how vendors compete.
  2. Oncology remains the anchor therapeutic area, driven by genomic profiling and the sheer scale of cancer cases worldwide, while rare and genetic disorders are expected to grow fastest, fueled by expanding genetic testing and sequencing capabilities.
  3. Services are growing faster than software licenses. As more organizations adopt these platforms, demand for implementation support, consulting, data curation, and training is accelerating.
  4. Interoperability standards are becoming a competitive edge. Vendors that make FHIR/HL7-based data exchange seamless are positioned to capture share as multi-source data integration becomes table stakes.
  5. Cross-border data initiatives are emerging, such as the International Health Data Space Initiative launched in July 2025, which aims to enable secure, privacy-preserving genomic data sharing across countries to accelerate AI-driven precision medicine and cancer research.
  6. Regional expansion is uneven but real. While North America leads today, Asia Pacific's rapid growth — powered by national genomics programs in China, Japan, South Korea, and India — signals where the next wave of adoption is coming from.

The Bottom Line

Precision medicine software sits at the intersection of two powerful trends: the collapsing cost of genomic data generation and the rising sophistication of AI to interpret it. The vendors that win will be the ones who can navigate regulatory complexity, solve interoperability challenges, and deliver cloud-scale platforms that clinicians actually trust. With the market on track to nearly triple by 2033, the opportunity — and the competition — is only intensifying.

Need insights tailored to your business? Request a customized version of this report to add the regions, segments, or data points most relevant to your strategy.

AI's Growing Role in the Patient Access Solutions Market

Healthcare's "front door" is getting a technology overhaul. Every appointment booked, insurance card scanned, and prior author...